KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Inventory (2018 - 2025)

Historic Change in Inventory for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $307000.0.

  • Castle Biosciences' Change in Inventory rose 12130.46% to $307000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 16164.38%. This contributed to the annual value of $193000.0 for FY2024, which is 9512.87% down from last year.
  • As of Q3 2025, Castle Biosciences' Change in Inventory stood at $307000.0, which was up 12130.46% from $1.5 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Change in Inventory high stood at $2.2 million for Q4 2023, and its period low was -$1.4 million during Q3 2024.
  • For the 5-year period, Castle Biosciences' Change in Inventory averaged around $318210.5, with its median value being $307000.0 (2025).
  • As far as peak fluctuations go, Castle Biosciences' Change in Inventory skyrocketed by 199166.67% in 2021, and later crashed by 33299.66% in 2025.
  • Quarter analysis of 5 years shows Castle Biosciences' Change in Inventory stood at -$355000.0 in 2021, then skyrocketed by 150.14% to $178000.0 in 2022, then skyrocketed by 1120.79% to $2.2 million in 2023, then dropped by 28.07% to $1.6 million in 2024, then tumbled by 80.36% to $307000.0 in 2025.
  • Its Change in Inventory stands at $307000.0 for Q3 2025, versus $1.5 million for Q2 2025 and -$1.3 million for Q1 2025.